Suppr超能文献

肌萎缩侧索硬化症患者的经皮胃空肠造口术

Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis.

作者信息

Strong M J, Rowe A, Rankin R N

机构信息

The Department of Clinical Neurological Sciences, The University of Western Ontario, London, Canada.

出版信息

J Neurol Sci. 1999 Oct 31;169(1-2):128-32. doi: 10.1016/s0022-510x(99)00235-x.

Abstract

We have performed a retrospective review of the use of a percutaneous gastrojejunostomy in patients with amyotrophic lateral sclerosis (ALS). Forty-one patients with initial bulbar manifestations of ALS and 32 patients with initial limb manifestations underwent a percutaneous gastrojejunostomy under fluoroscopic control using the Rankin gastrojejunostomy tube. Survival characteristics were compared with 86 bulbar onsetting and 207 limb onsetting ALS patients who did not require nutritional support. The 30-day mortality rate was 9.6% (respiratory death in three bulbar onsetting patients and four limb onsetting patients) and the 30 day morbidity rate was 4.1% (one operative site infection and intraperitoneal leakage in two patients). The most frequent long-term complication was the requirement for tube changing (blockage in six; dislodgment in two). Gastric reflux was not described amongst the treated patients. Overall survivorship (symptom onset to death) was less in the bulbar onsetting patients receiving a gastrojejunostomy tube than in the control population (median survival 22.0 vs. 33.7 months, respectively, P=0.005). As a group, the median survivorship for limb onsetting patients was not different for those receiving a gastrojejunostomy than for those who did not. However, a significant reduction in survival was observed in limb onsetting patients receiving a gastrojejunostomy early in the course of their disease (P=0.001) compared to those with a longer duration prior to the procedure. This was not observed in the bulbar onsetting patients. In both patient populations, no relationship was observed between survival post-gastrojejunostomy and the severity of pulmonary involvement at the time of the intervention, serum chloride, or age at onset. These studies demonstrate that a percutaneous gastrojejunostomy is a well-tolerated and safe alternative technique for enteral nutritional support in ALS patients. It also offers the advantage of not requiring either a general anaesthetic at the time of the procedure or instrumentation through the oropharynx. We have also observed that limb onsetting patients requiring a gastrojejunostomy early in the course of their illness are in a distinctive, less favorable, prognostic group.

摘要

我们对肌萎缩侧索硬化症(ALS)患者经皮胃空肠造口术的使用情况进行了回顾性研究。41例以延髓症状为首发表现的ALS患者和32例以肢体症状为首发表现的患者,在透视引导下使用兰金胃空肠造口管进行了经皮胃空肠造口术。将其生存特征与86例延髓起病和207例肢体起病且无需营养支持的ALS患者进行了比较。30天死亡率为9.6%(3例延髓起病患者和4例肢体起病患者死于呼吸衰竭),30天发病率为4.1%(1例手术部位感染,2例患者发生腹腔内渗漏)。最常见的长期并发症是需要更换造瘘管(6例堵塞;2例移位)。在接受治疗的患者中未提及胃食管反流。接受胃空肠造口管的延髓起病患者的总体生存期(从症状出现到死亡)短于对照组人群(中位生存期分别为22.0个月和33.7个月,P=0.005)。作为一个群体,接受胃空肠造口术的肢体起病患者的中位生存期与未接受该手术的患者没有差异。然而,与手术前病程较长的肢体起病患者相比,在疾病早期接受胃空肠造口术的肢体起病患者的生存期显著缩短(P=0.001)。在延髓起病患者中未观察到这种情况。在这两类患者群体中,胃空肠造口术后的生存期与干预时肺部受累的严重程度、血清氯水平或发病年龄之间均未观察到相关性。这些研究表明,经皮胃空肠造口术是ALS患者肠内营养支持的一种耐受性良好且安全的替代技术。它还具有在手术时无需全身麻醉或经口咽器械操作的优点。我们还观察到,在疾病早期需要进行胃空肠造口术的肢体起病患者属于一个独特的、预后较差的群体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验